

1 **Therapeutic Brief**

[Creative Commons 4.0](#)

2 **Description:**

3 *Therapeutic Brief is designed to feature a drug specifically for aging intervention or treatment of an age-related*
4 *disease. The intent is to raise awareness of drugs with potential for aging and age-related disease research for*
5 *clinical trials.*

6 **Title: Short-term oral rapamycin prevents age-related learning**
7 **impairment in mice**

8 *[Suggestions: No more than 20 words. No abbreviations except for standardized ones e.g., DNA, RNA, gene or*
9 *protein names, etc.]*

10 **Forename Surname^a, Forename Surname^{a,b}, Forename Surname^c**

11 ^a *Department, Institution, City Postcode, Country.*

12 ^b *Department, Institution, City, State Postcode, Country.*

13 ^c *Department, Institution, City Postcode, Province, Country.*

14 **Correspondence to:** Prof./Dr. Forename Surname, Department, Institution, Detailed Address, City Postcode,
15 Country.

16 E-mail: xxxx@xxxx.xxx

17 **How to Use This Template**

18 *This template shows the manuscript structure that can be used in an original article: Abstract, Keywords,*
19 *Introduction, Methods, Results, Discussion, Declarations and References. Please note that each part has a*
20 *corresponding style, which authors should follow. Please note that the fonts in gray show writing requirements.*
21 *For any questions, you may contact the [editorial office](#).*

22 **Abstract**

23 *[Suggestions: No more than 250 words. No citations. Define abbreviations at their first mention.]*

24 Abstract is a brief summary of an article, which helps the readers quickly ascertain the paper's main
25 content. In this part, authors may mention writing purpose, background, case presentation, conclusion,
26 *etc.*

27 **Keywords:** Aging, older patients, chronic heart failure, drug therapy

28 *[Please suggest 3-6 keywords which can be used for describing the content of the manuscript and will enable the*
29 *full text of the manuscript to be searchable online.]*

30 **Main text.** In this section, authors should describe the main text of the manuscript in detail.

31 *Tips:*

32 ● *All drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration, should be*
33 *identified precisely;*

34 ● *When reporting studies on human beings or animals, authors should strictly follow the Helsinki*
35 *Declaration (available at <http://www.wma.net/en/30publications/10policies/b3/>) and other related publishing*
36 *ethical standards.*

37 **Table 1** (other forms: Tables 1 and 2; Tables 1-3), **Equation (1)** [other forms: Equations (2) and (3);
38 Equations (4-6)] and **Figure 1** (other forms: Figure 1A and B; Figure 2A-C; Figures 1 and 2A; Figures 1,
39 2A and 3-5) show the examples of diagrams. All the tables, equations and figures should be cited in
40 sequence in the main content near to the first time they appear. For supplementary material, authors may
41 cite table, equation and figure like **Supplementary Table 1**, **Supplementary Equation (1)** and
42 **Supplementary Figure 1**.

43 *Tips:*

- 44 ● *Results should be presented in a logical sequence;*
- 45 ● *Avoid redundant explanations to all the data from the tables or illustrations.*

46 **Table 1. This is a table caption. A summary description of this table should be written here**

Authors	Regimen	n	Age (year)	CR (%)	2-year (3-year) EFS/PFS (%)	2-year (3-year) OS (%)
Our current study	CHOP	251	17-82	69.8	55.3 (46.0)	58.0 (52.0)
	CVP	67	45-87	29.9*	18.0 (12.0)*	25.0 (19.0)*
Khaled et al. ^[1]	CHOP	40	19-75	67	54 (54)	82 (71)
Burton et al. ^[2]	CHOP	105	22-66	70	4-year PFS: 56	4-year OS: 65
	CIOP	106	25-67	52	4-year PFS: 40*	4-year OS: 56 [#]

47 This part is footer. **P* < 0.05, [#]*P* ≥ 0.05. EFS: event-free survival; PFS: progression-free survival; OS: overall survival; CHOP:
 48 cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP: cyclophosphamide, vincristine, and prednisone; CIOP:
 49 cyclophosphamide, idarubicin, vincristine, and prednisone; CR: complete response. This table is cited with permission from Li et
 50 al.^[1] published in xxx


51 *Table notes:*


- 52 ● *Tables should be cited in numeric order and placed after the paragraph where it is first cited;*
- 53 ● *The table caption should be placed above the table and labeled sequentially (e.g., Table 1, Table 2);*
- 54 ● *Tables should be provided in editable form like DOC or DOCX format (picture is not allowed);*
- 55 ● *Abbreviations and symbols used in table should be explained in footnote;*
- 56 ● *Explanatory matter should also be placed in footnotes;*
- 57 ● *Non-English words should be avoided;*
- 58 ● *Permission for use of copyrighted materials from other sources, including re-published, adapted, modified,*
 59 *or partial tables from the internet, must be obtained. It is authors' responsibility to acquire the licenses, to*
 60 *follow any citation instruction requested by third-party rights holders, and cover any supplementary*

$$S_i = \sum_{j=1}^n W_j X_j \tag{1}$$

61 *Equation note:*

- 62 ● *Equations should be provided in editable form (image file format is not allowed).*





C

63 **Figure 1.** We present examples of electron micrograph, non-editable and editable images in Figure 1A-C.
 64 A: description of what the Figure 1A is; B: description of what the Figure 1B is; C: description of what
 65 the Figure 1C is.

66 *Figure notes:*

- 67 ● *Figures should be cited in numeric order (e.g., Figure 1, Figure 2) and placed after the paragraph where it*
 68 *is first cited;*
- 69 ● *Figures can be submitted in format of tiff, psd, AI or jpeg, with resolution of 300-600 dpi;*
- 70 ● *Diagrams with describing words (including, flow chart, coordinate diagram, bar chart, line chart, and*
 71 *scatter diagram, etc.) should be editable in word, excel or powerpoint format. Non-English information*
 72 *should be avoided;*
- 73 ● *Please use the font in “Times New Roman” format for the text in the chart*
- 74 ● *Labels, numbers, letters, arrows, and symbols in figure should be clear, of uniform size, and contrast with*
 75 *the background;*
- 76 ● *Symbols, arrows, numbers, or letters used to identify parts of the illustrations must be identified and*
 77 *explained in the legend;*
- 78 ● *Internal scale (magnification) should be explained and the staining method in photomicrographs should be*
 79 *identified;*
- 80 ● *All non-standard abbreviations should be explained in the legend;*
- 81 ● *Authors should pay attention to the protection of patients’ rights, such as privacy and portrait, and obtain*
 82 *signed patient consent from authors before using any personal information of patients. The patient’s*
 83 *portrait with full characters and his/her real name is not allowed for use;*
- 84 ● *Permission for use of copyrighted materials from other sources, including re-published, adapted, modified,*
 85 *or partial figures and images from the internet, must be obtained. It is authors’ responsibility to acquire the*
 86 *licenses, to follow any citation instruction requested by third-party rights holders, and cover any*
 87 *supplementary charges.*

88 **DECLARATIONS**

89 **Acknowledgments**

90 Anyone who contributed towards the article but does not meet [the criteria](#) for authorship, including
 91 those who provided professional writing services or materials, should be acknowledged. Authors should
 92 obtain permission to acknowledge from all those mentioned in the Acknowledgments section. This
 93 section is not added if the author does not have anyone to acknowledge.

94 **Authors’ contributions**

95 Single author:

96 The author contributed solely to the article.

97 Two or more authors:

98 Made substantial contributions to conception and design of the study and performed data analysis and
99 interpretation: Salas H, Castaneda WV;
100 Performed data acquisition, as well as provided administrative, technical, and material support: Castillo
101 N, Young V
102 ...

103 **Availability of data and materials**

104 Authors should declare where the data supporting their findings can be found. Data can be deposited into
105 data repositories or published as supplementary information in the journal. Authors who cannot share
106 their data should state that the data will not be shared and explain it.

107 If a manuscript does not involve such issue, please state “Not applicable.” in this section.

108 **Financial support and sponsorship**

109 If there are sources of funding for the study reported, any relevant grant numbers and the link of funder’s
110 website should be provided if any. The role of the funding body in the experiment design, collection,
111 analysis and interpretation of data, and writing of the manuscript should be declared:
112 This work was supported by Grant name XX (No. XXXX; No. XXX)...

113 If there is no grant:
114 None.

115 **Conflicts of interest**

116 If there are any potential conflicts of interest that may be perceived as inappropriately influencing the
117 representation or interpretation of reported research results, please declare here.

118 If not, please write as “All authors declared that there are no conflicts of interest.”.

119 Some authors may be bound by confidentiality agreements. In such cases, in place of itemized
120 disclosures, we will require authors to state “All authors declare that they are bound by confidentiality
121 agreements that prevent them from disclosing their conflicts of interest in this work.”.

122 If authors are unsure whether conflicts of interest exist, please refer to the “Conflicts of Interest” of ANT
123 [Editorial Policies](#) for a full explanation.

124 **Ethical approval and consent to participate**

125 Research involving human subjects, human material or human data must be performed in accordance
126 with the [Declaration of Helsinki](#) and approved by an appropriate ethics committee. An informed consent
127 to participate in the study should also be obtained from participants, or their parents or legal guardians
128 for children under 16. A statement detailing the name of the ethics committee (including the reference
129 number where appropriate) and the informed consent obtained must appear in the manuscripts reporting
130 such research.

131 Studies involving animals and cell lines must include a statement on ethical approval. More
132 information is available at [Editorial Policies](#).

133 If the manuscript does not involve such issue, please state “Not applicable.” in this section.

134 **Consent for publication**

135 Manuscripts containing individual details, images or videos, must obtain consent for publication from
136 that person, or in the case of children, their parents or legal guardians. If the person has died, consent for
137 publication must be obtained from the next of kin of the participant. Manuscripts must include a
138 statement that a written informed consent for publication was obtained. Authors do not have to submit
139 such content accompanying the manuscript. However, these documents must be available if requested.

140 If the manuscript does not involve this issue, state “Not applicable.” in this section.

141 **Copyright**

142 Authors retain copyright of their works through a Creative Commons Attribution 4.0 International
143 License that clearly states how readers can copy, distribute, and use their attributed research, free of
144 charge. Authors are required to sign License to Publish before formal publication.

145 REFERENCES

146 Identify references in the text by alphabetic numerals e. g. [1-3] or [1, 2]. The reference list should be
147 separated from the text; references must be numbered consecutively in the order in which they are
148 mentioned in the text. Use the style of the examples below, which are based on the formats used by the
149 NLM in Index Medicus. The titles of journals should be abbreviated according to the style used in Index
150 Medicus. Use complete name of the journal for non-indexed journals. Avoid using abstracts as references.
151 Information from manuscripts submitted but not accepted should be cited in the text as "unpublished
152 observations" with written permission from the source. Avoid citing a "personal communication" unless
153 it provides essential information not available from a public source, in which case the name of the person
154 and date of communication should be cited in parentheses in the text.

155 Reference to a journal publication:

156 Ormsbee MJ, Prado CM, Ilich JZ, Purcell S, Siervo M, Folsom A, *et al.* Osteosarcopenic obesity: the role
157 of bone, muscle, and fat on health. *J Cachexia Sarcopenia Muscle*, 2014, 5(3): 183-192.

158 Reference to a book

159 Voet D, Voet JG. *Biochemistry*. New York: John Wiley & Sons 1990. 1223 p.

160 Reference to a website

161 Cancer Research UK, 1975. Cancer statistics reports for the UK.
162 <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13.03.03).

163 *For other types of references please refer to U.S. National Library of Medicine*
164 *(https://www.nlm.nih.gov/bsd/uniform_requirements.html). The names of journals should be Italic.*

165 The journal also recommends that authors prepare references with a bibliography software package, such
166 as EndNote to avoid typing mistakes and duplicated references.

167 Supplementary Materials

168 Additional data and information can be uploaded as Supplementary Materials to accompany the
169 manuscripts. The supplementary materials will also be available to the referees as part of the peer-review
170 process. Any file format is acceptable, such as data sheet (word, excel, csv, cdx, fasta, pdf or zip files),
171 presentation (powerpoint, pdf or zip files), image (cdx, eps, jpeg, pdf, png or tiff), table (word, excel, csv
172 or pdf).